Description

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates[1][2][3].-4°C (Powder, protect from light, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C70H99N7O21-Citation–References-[1]Watanabe K, et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4;10(2):161-174.|[2]Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.|[3]Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.-CASNumber-2130869-18-8-MolecularWeight-1374.57-Compound Purity-99.82-SMILES-C=C1C[C@@]2([H])O[C@@]1([H])CC[C@]3([H])O[C@](C([C@H](C)C3)=C)([H])C[C@@]4([H])[C@]([C@@H](OC)[C@@H](C[C@H](O)CNC(OCC5=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCOCCOCCN6C(C=CC6=O)=O)=O)=O)=O)C=C5)=O)O4)([H])CC(C[C@]7([H])O[C@]8([H])[C@]9([H])O[C@@](O[C@@]([H])[C@@](O[C@]9([H])[C@@]([H])O[C@@]8([H])CC7)([H])C)CC2)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 10 mg/mL-Target-Drug-Linker Conjugates for ADC-Isoform-Traditional Cytotoxic Agents-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related